Iridian Asset Management’s Axsome Therapeutics AXSM Stock Holding History

Iridian Asset Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-15,000	Closed	-$567K	–	58
2021 Q4	$567K	Hold	15,000	–	–	0.03%	65
2021 Q3	$494K	Sell	15,000 -7,500	-33%	-$292K	0.02%	76
2021 Q2	$1.52M	Buy	22,500 +19,300	+603%	+$1.16M	0.03%	68
2021 Q1	$181K	Buy	+3,200	New	+$225K	﹤0.01%	116
2020 Q2	–	Sell	-10,200	Closed	-$600K	–	77
2020 Q1	$600K	Buy	+10,200	New	+$831K	0.01%	64

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Iridian Asset Management's AXSM Position: Q1 2026 in Review

Iridian Asset Management reduced its Axsome Therapeutics (AXSM) stake by 8.5% in Q1 2026, selling an estimated $1.09M and leaving 67,491 shares worth $11.4M. The position accounts for 4.62% of the portfolio, ranked #8.

Iridian Asset Management first reported a position in AXSM in Q1 2019 and has held it in 29 quarters since. The position peaked at $168M in Q4 2020. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

Iridian Asset Management held 67,491 shares of Axsome Therapeutics worth $11.4M as of Q1 2026.
Iridian Asset Management sold 6,292 Axsome Therapeutics shares in Q1 2026, an estimated $1.09M.
Axsome Therapeutics made up 4.62% of Iridian Asset Management's portfolio in Q1 2026, its #8 holding.
Iridian Asset Management first reported a position in Axsome Therapeutics in Q1 2019 and has held it in 29 quarters since.
Iridian Asset Management's Axsome Therapeutics position peaked at $168M in Q4 2020.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Iridian Asset Management's 13F filing for Q1 2026, filed 24 Apr 2026.